Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -1.18% 167.00 167.00 169.00 174.00 167.00 170.00 1,078,723 16:29:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -4.8 -3.6 - 334

Synairgen plc COVID-19 Clinical Programme Update

18/12/2020 7:00am

UK Regulatory (RNS & others)


Synairgen (LSE:SNG)
Historical Stock Chart


From Dec 2020 to Mar 2021

Click Here for more Synairgen Charts.

TIDMSNG

RNS Number : 0893J

Synairgen plc

18 December 2020

Press release

Synairgen plc

('Synairgen' or the 'Company')

COVID-19 Clinical Programme Update

   -    SNG001 given Fast Track designation and IND cleared by the US FDA 
   -    Phase III trial design adapted which will expedite results 
   -    Phase III trial to commence dosing in UK imminently 

Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company's Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path.

Update to Phase III trial (SG018) protocol in COVID-19 patients

Following discussions with the regulatory agencies, the trial has been amended as follows:

-- Removal of the lower dose arm, thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610 patients

-- Addition of a second primary endpoint. The primary endpoints are now 'time to hospital discharge' and 'time to recovery'. The primary assessment of efficacy will be supported by the key secondary endpoint of 'progression to severe disease or death' and other secondary endpoints. Both primary endpoints have at least 90% power to detect a statistically significant effect of SNG001 compared to placebo

   --      Addition of assessments for Long COVID-19 symptoms on day 60 and day 90 

Initiation of the first SG018 sites has commenced in the UK, with dosing expected to commence imminently. The SG018 trial was deemed an Urgent Public Health study and recognised as a National Priority by the National Institute for Health Research (NIHR) in October 2020.

Investigational New Drug clearance and Expedited Regulatory Pathway granted from the FDA

Synairgen's Investigational New Drug (IND) application to the FDA to evaluate SNG001 as a treatment for patients with COVID-19, has been cleared, enabling Synairgen to initiate its SG018 trial in the US. Furthermore, the FDA has awarded SNG001 Fast Track status, enhancing the ability of Synairgen to interact with the FDA and shortening review timelines.

Update on the SG016 home trial in COVID-19 patients

This trial targets patients with a positive SARS-CoV-2 test result who are aged over 65 and those over the age of 50 with 'high risk' medical conditions. It is a trial designed to make it easy and safe for trial participants and researchers to conduct the research; all supplies for the trial are delivered directly to the patient's door by courier, and all trial visits and assessments are conducted virtually by video call. After a slow start in the summer, recruitment and dosing are now progressing well with a noticeable increase in the last two months. Those interested in participating in the trial can visit www.covidtrialathome.com .

Richard Marsden, CEO of Synairgen, said: "With this adaptation we should be able to reduce the time taken to complete the trial, which, together with an expedited review from the FDA, could allow us to get this therapy approved for patient use in COVID-19 more rapidly. With trial sites now being set up, we anticipate dosing the first patients imminently. SNG001(1) is one of the few potential treatments to have shown efficacy against severe viral lung infections such as COVID-19, and multiple approaches will be needed to minimise the impact of this deadly virus.

"There remains a great need to develop breakthrough treatments for patients who become ill with COVID-19, despite the recent successes from the vaccine developers. This is especially important if vaccine uptake is poor for any reason, or if any mutations in the SARS-CoV-2 virus render the vaccines less effective."

References

1. The Lancet Respiratory Medicine: "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial". Monk, P D PhD, et al., 12 November 2020, accessible here .

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: +44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD, and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see https://www.synairgen.com

COVID-19

COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people and those with co-morbidities such as heart and lung complications or diabetes are at greatest risk of developing severe or fatal disease.

Synairgen is currently recruiting into a trial of SNG001 in COVID-19 patients (over the age of 65, or those over 50 with a pre-existing medical condition) in the home setting. For more information about the trial please visit www.covidtrialathome.com .

Interferon beta applicability to COVID-19

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses. There is growing evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility in 'at-risk' patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2, have evolved mechanisms which suppress endogenous IFN-beta production, helping the virus to evade the innate immune system. The addition of exogenous IFN-beta before or during viral infection of lung cells in vitro either prevents or greatly reduces viral replication. Synairgen's SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. It is pH neutral, and is free of mannitol, arginine and human serum albumin, making it suitable for inhaled delivery direct to the site of action. Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCMZMMZMNNGGZZ

(END) Dow Jones Newswires

December 18, 2020 02:00 ET (07:00 GMT)

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart
ADVFN Advertorial
Your Recent History
LSE
SNG
Synairgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210306 11:59:33